Retinitis pigmentosa is a kind of cortex on retinal pigment degeneration, chronic, progressive visual function, genetic, nutrition is not virtuous, retinal degenerative eye disease, the disease involving the eyes, men more than women, more incidence of 10 to 20 years old, a few people with the disease in the home, the faster progress in the earlier onset, curative effect is poorer, old age comes on slowly.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Retinitis Pigmentosa (Retinitis) estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Retinitis Pigmentosa (Retinitis) is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Retinitis Pigmentosa (Retinitis) is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Retinitis Pigmentosa (Retinitis) is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Retinitis Pigmentosa (Retinitis) include Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences and Dompe Farmaceutici SpA, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.